News Astellas breaks new ground in menopause with Veozah Astellas has become the first drugmaker to bring a drug in the neurokinin 3 (NK3) receptor antagonist class to the US market, after getting FDA approval of fezolinetant fo
R&D Health Innovators – Jennifer Schranz In the rare and ultra-rare disease space, the paucity of both data and patients makes everything about research and development more complicated.
R&D Inside the new world of healthcare data These days, real-world data collection is in vogue and not hard to come by in healthcare research.